Biopharmx (BPMX) Stock Price, News & Analysis

Company Overview

BiopharmX Corp. is a clinical‐stage biopharmaceutical company focused on the development and commercialization of innovative therapies for ophthalmic and dermatologic diseases. Headquartered in Miami, Florida, the company applies proprietary drug delivery technologies and novel anti‐inflammatory compounds to address a range of inflammatory conditions affecting the eye and skin.

The company’s pipeline includes topical and ocular formulations designed to target underlying disease pathways with enhanced efficacy and tolerability. Lead candidates are being evaluated for indications such as blepharitis, dry eye disease and periocular inflammatory disorders. By leveraging formulation expertise, BiopharmX aims to improve patient outcomes with therapies that offer once-daily or twice-daily dosing regimens.

Founded in the early 2010s, BiopharmX has pursued a series of preclinical and early‐stage clinical programs, drawing on collaborations with academic research centers and contract development organizations. Strategic partnerships have been established to support formulation development, manufacturing scale‐up and regulatory guidance, positioning the company for potential Phase 3 studies and eventual commercialization.

BiopharmX serves the U.S. market and is exploring licensing opportunities in Europe and Asia to broaden its global reach. The company is led by an experienced management team with deep expertise in drug development, regulatory affairs and commercial strategy, supported by a board of directors with backgrounds in specialty pharmaceuticals and biotechnology.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 336,508 shs
• Average Volume: 2.15 million shs
• Market Capitalization: $111.86 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

BPMX Stock Analysis - Frequently Asked Questions

How were Biopharmx's earnings last quarter?

Biopharmx Corp (NYSEAMERICAN:BPMX) released its quarterly earnings results on Tuesday, December, 10th. The biotechnology company reported ($1.68) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.64) by $0.96.

When did Biopharmx's stock split?

Biopharmx shares reverse split on Tuesday, May 19th 2020.The 1-12 reverse split was announced on Friday, May 15th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Monday, May 18th 2020. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

How do I buy shares of Biopharmx?

Shares of BPMX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Biopharmx own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Biopharmx investors own include Sarepta Therapeutics (SRPT), Netlist (NLST), Neovasc (NVCN), Hawkins (HWKN), LadRx (CYTR), Novavax (NVAX) and Protalix BioTherapeutics (PLX).

Company Calendar

• Last Earnings: 12/10/2019
• Today: 7/18/2025

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: NYSEAMERICAN:BPMX
• Previous Symbol: NYSE:BPMX
• CIK: N/A
• Web: www.biopharmx.com
• Phone: +1-650-8895020
• Fax: N/A
• Employees: 17
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 18,278,000
• Free Float: N/A
• Market Cap: $111.86 million
• Optionable: Not Optionable
• Beta: N/A